CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 6.5% – Here’s What Happened

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) traded up 6.5% on Wednesday . The company traded as high as $0.12 and last traded at $0.12. Approximately 13,369,292 shares were traded during trading, an increase of 139% from the average session volume of 5,602,099 shares. The stock had previously closed at $0.11.

Analyst Ratings Changes

Separately, Maxim Group raised shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a report on Tuesday, September 10th.

CNS Pharmaceuticals Stock Performance

The business has a 50-day simple moving average of $0.12 and a 200-day simple moving average of $0.42. The company has a market cap of $6.72 million, a price-to-earnings ratio of 0.00 and a beta of 2.55.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.